Short-term clinico-radiographic response to super-selective intra-arterial cerebral infusion of bevacizumab for the treatment of vestibular schwannomas in neurofibromatosis type 2

Interventional Neuroradiology

Volumn 18, Issue 2, 2012, Pages 127-132

  Riina, Howard A ^a   Burkhardt, J K ^b   Santillan, A ^b   Bassani, L ^a   Patsalides, A ^b   Boockvar, J A ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Bevacizumab; Neurofibromatosis type 2; Superselective intra arterial cerebral infusion; Vestibularis schwannoma

Indexed keywords

BEVACIZUMAB;

ABSENCE OF SIDE EFFECTS; ACOUSTIC NEURINOMA; ADULT; ARTICLE; BLOOD BRAIN BARRIER; CASE REPORT; FEMALE; HEARING LOSS; HUMAN; MALE; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PONS ANGLE; TREATMENT RESPONSE;

EID: 84863447314     PISSN: 15910199     EISSN: None     Source Type: Journal    
DOI: 10.1177/159101991201800201     Document Type: Article

References (16)

1. Evans DG, Moran A, King A, et al. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol. 2005; 26: 93-97. (Pubitemid 40130216)
2. Evans GR, Lloyd SK, Ramsden RT. Neurofibromatosis type 2. Adv Otorhinolaryngol. 2011; 70: 91-98.
3. Samii M, Matthies C, Tatagiba M. Management of vestibular schwannomas (acoustic neuromas): auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2. Neurosurgery. 1997; 40: 696-705; discussion 705-696.
4. Murphy ES, Suh JH. Radiotherapy for vestibular schwannomas: a critical review. Int J Radiat Oncol Biol Phys. 2011; 79: 985-997.
5. Philip R, Prepageran N, Raman R, et al. Surgical management of large acoustic neuromas: a review. Med J Malaysia. 2009; 64: 294-297.
6. nd, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009; 361: 358-367.
7. Mautner VF, Nguyen R, Kutta H, et al. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol. 2010; 12: 14-18.
8. Mautner VF, Nguyen R, Knecht R, et al. Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation. Ann Oncol. 2010; 21: 2294-2295.
9. Uesaka T, Shono T, Suzuki SO, et al. Expression of VEGF and its receptor genes in intracranial schwannomas. J Neurooncol. 2007; 83: 259-266. (Pubitemid 46952236)
10. Wong HK, Lahdenranta J, Kamoun WS, et al. Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer Res. 2010; 70: 3483-3493.
11. Boockvar JA, Tsiouris AJ, Hofstetter CP, et al. Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article. J Neurosurg. 2011; 114: 624-632.
12. Burkhardt J-K, Riina HA, Shin BJ, et al. Intra-arterial delivery of bevacizumab after blood brain barrier disruption for the treatment of recurrent glioblastoma: progression free survival and overall survival. World Neurosurg, in press, 2011.
13. Riina HA, Fraser JF, Fralin S, et al. Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma. J Exp Ther Oncol. 2009; 8: 145-150.
14. Riina HA, Knopman J, Greenfield JP, et al. Balloon-assisted superselective intra-arterial cerebral infusion of bevacizumab for malignant brainstem glioma. A technical note. Interv Neuroradiol. 2010; 16: 71-76.
15. Yamakami I, Kobayashi E, Iwadate Y, et al. Hypervascular vestibular schwannomas. Surg Neurol. 2002; 57: 105-112. (Pubitemid 34211335)
16. Burkhardt J-K, Riina HA, Shin BJ, et al. Intra-arterial chemotherapy for malignant gliomas. A critical analysis. Interv Neuroradiol. 2011; 17: 286-295.